New antimicrobials on the horizon.
- Author:
Mi Suk LEE
1
Author Information
1. Division of Infectious Diseases, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea.
- Publication Type:Review
- Keywords:
Anti-infective agents;
Drug resistance;
Investigational new drugs
- MeSH:
Aminoglycosides;
Anti-Bacterial Agents;
Anti-Infective Agents;
Bacteria;
Carbapenems;
Cephalosporins;
Daptomycin;
Drug Resistance;
Drugs, Investigational;
Glycopeptides;
Minocycline;
Pyrimidines;
Trastuzumab
- From:Korean Journal of Medicine
2009;77(1):35-51
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Recently, infections caused by antibiotic-resistant bacteria continue to climb in the community and the hospital around the world. Our current antimicrobial agents are gradually becoming ineffective and a new pipeline of powerful compounds is needed urgently. A number of new antimicrobial compounds are in development, including novel glycopeptides (dalbavancin, telavancin, and oritavancin), daptomycin, tigecycline, ceftobiprole, iclaprim, and doripenem. The article will provide an update on the newly marketed and potentially effective antibacterial agents in the late-stage development pipeline
